Long-term survival after pancreatic cancer treatment

Chen, Emery L.; Prinz, Richard A.

doi:10.1016/j.amjsurg.2007.05.015

Cited by 8 publications

(10 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the BxPC-3 model, retention of [ 18 F]FBA-PEG 28 -A20FMDV2 in tumors was 12-fold greater than retention of the non-PEGylated [ 18 F]FBA-A20FMDV2. Tumor/pancreas and tumor/blood ratios of >23:1 and >47:1, respectively, were achieved with [ 18 F]FBA-PEG 28 -A20FMDV2 at 4 h. The ability to non-invasively detect regional tumor invasion or occult metastatic disease using α v β 6 PET imaging would have a large impact on patient management, reducing the number of unnecessary surgeries of unresectable disease (23). …”

Section: Introductionmentioning

confidence: 99%

Targeted In vivo Imaging of Integrin αvβ6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model

Hausner¹,

et al. 2009

View full text Add to dashboard Cite

The cell surface receptor A v B 6 is epithelial specific, and its expression is tightly regulated; it is low or undetectable in adult tissues but has been shown to be increased in many different cancers, including pancreatic, cervical, lung, and colon cancers. Studies have described A v B 6 as a prognostic biomarker linked to poor survival. We have recently shown the feasibility of imaging A v B 6 in vivo by positron emission tomography (PET) using the peptide [18 F]FBA-A20FMDV2. Here, we describe improved A v B 6 imaging agents and test their efficacy in a mouse model with endogenous A v B 6 expression. The modified compounds maintained high affinity for A v B 6 and >1,000-fold selectivity over related integrins (by ELISA) and showed significantly improved A v B 6 -dependent binding in cell-based assays (>60% binding versus <10% for [ 18 F]FBA-A20FMDV2). In vivo studies using either a melanoma cell line (transduced A v B 6 expression) or the BxPC-3 human pancreatic carcinoma cell line (endogenous A v B 6 expression) revealed that the modified compounds showed significantly improved tumor retention. This, along with good clearance of nonspecifically bound activity, particularly for the new radiotracer [18 F]FBA-PEG 28 -A20FMDV2, resulted in improved PET imaging. Tumor/pancreas and tumor/blood biodistribution ratios of >23:1 and >47:1, respectively, were achieved at 4 hours. Significantly, [18 F]FBA-PEG 28 -A20FMDV2 was superior to 2-[ 18 F]fluoro-2-deoxy-D-glucose ([ 18 F]FDG) in imaging the BxPC-3 tumors. Pancreatic ductal adenocarcinoma is highly metastatic and current preoperative evaluation of resectability using noninvasive imaging has limited success, with most patients having metastases at time of surgery. The fact that these tumors express A v B 6 suggests that this probe has significant potential for the in vivo detection of this malignancy, thus having important implications for patient care and therapy.

show abstract

Section: Introductionmentioning

confidence: 99%

Targeted In vivo Imaging of Integrin αvβ6 with an Improved Radiotracer and Its Relevance in a Pancreatic Tumor Model

Hausner¹,

et al. 2009

View full text Add to dashboard Cite

show abstract

“…Some reasons to explain the better prognosis of pancreatic cancer in last years have been the advances in perioperative care, surgical technique, and early detection of complications, resulting in a decrease of the surgical mortality of pancreatectomy from 25% in the late 70s, to less than 5% today (21)(22)(23)(24)28). In our series, mortality was 3.3% (one patient).…”

Section: Discussionmentioning

confidence: 62%

Multidisciplinary approach and multimodal therapy in resected pancreatic cancer: Observational study

Morales

Cuadrado

Noguera

et al. 2011

Rev. esp. enferm. dig.

View full text Add to dashboard Cite

Objective: analysis and evaluation of a multidisciplinary approach, postoperative results and survival of a group of patients with resected pancreatic cancer after a multimodal therapy. Design: descriptive, prospective and observational study. Patients: between January 2004 and December 2004, 124 patients with pancreatic cancer were evaluated. In 30 patients pancreatic resection was performed, and they are the object of this study. Results of preoperative evaluation, postoperative morbidity and mortality, and long term survival were studied. Results: diagnostic evaluation was completed in ambulatory basis in 20% of the patients. In 63% of cases, admission was done in the same day of surgery. In 3 patients (9%), tumor resection was not achieved, therefore, concordance between radiological and surgical resectability rate was 91%. Resectability rate was 24.1%. Surgical Mortality was 3.3%, with a global morbidity rate of 56.6%. Survival at one, two, three and, four years was 76.2%, 56.3%, 43%, y 27.3% respectively. Conclusions: technological development and coordination of efforts in multidisciplinary teams offer an accurate evaluation of tumor involvement, and may reduce the number of laparotomies without tumor resection. The application of a systematic and generalized multimodal treatment in pancreatic cancer is progressively showing a tendency of progressive increase in resectability and survival rates in pancreatic cancer.

show abstract

“…or metastatic disease (2-6 mos. ), reflective of extent of disease rather than treatment [2][3][4][5][6].…”

Section: Editorialmentioning

confidence: 99%

“…Neoadjuvant therapy has had a positive impact on cancers of the stomach and rectum and is generating similar interest for CaP [5]. The largest study (327 CaP patients) with impressive actual 5 (27%) and 10 (14%) year survival utilized neoadjuvant therapy for resectable and borderline resectable lesions [6]. Beginning in the 1980's we altered our approach to CaP based on the dismal outcomes with existing therapy and acceptance of its systemic nature [7].…”

Section: Editorialmentioning

confidence: 99%